PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.62
0.02 (1.25%)
▲
5d:
-16.49%
30d:
-27.68%
90d:
-35.97%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
PROK is down 14.1% this week, but smart money is accumulating calls. Top strike: $3 2026-04-17 with 837 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PROK is down 16.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PROK is down 16.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.62, which is considered oversold relative to its 30-day fair value range of $1.90 to $2.37.
Technical Outlook: Technically, PROK is in a uptrend. Immediate support is located at $1.56, while resistance sits at $2.20.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+285.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PROK is in a uptrend. Immediate support is located at $1.56, while resistance sits at $2.20.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+285.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.90 -
$2.37
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 285.8% below Wall St target ($6.25)
- WARNING: Recommendation downgraded due to -16.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.90 -
$2.37
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.56
Resistance Level
$2.20
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.22
Wall Street Target
$6.25
(+285.8%)
Revenue Growth (YoY)
196.1%
Share & Embed Analysis
Last updated: March 30, 2026 6:05 PM ET
Data refreshes hourly during market hours. Next update: 7:05 PM
Data refreshes hourly during market hours. Next update: 7:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Jg Pereira
SELL
502136 shares
2025-11-13
Brian Jg Pereira
SELL
255026 shares
2025-11-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
